pHion Therapeutics was founded in 2017 based on technology developed in the School of Pharmacy at Queen’s University Belfast U.K. It is a UK-based vaccine development company, developing a pipeline of therapeutic and prophylactic vaccines focused on viral infections and oncology.
pHion focuses on developing the next-generation peptide-based drug delivery system.
The company’s proprietary RALA platform can deliver anionic molecules such as mRNA and DNA in a stealth-like way, evading detection, to generate a potent antigen-specific CD8+ T-cell response.
The pHion Therapeutics team includes inventors, scientists, and business development professionals from a variety of life sciences backgrounds.
invoX investment event
In June 2021, invoX acquired a majority stake in pHion Therapeutics.
pHion recently celebrated its 5-year anniversary which coincided with a move to new premises at the Catalyst Science Park, Belfast.
pHion’s new R&D laboratory and office space